Ashland price target lowered to $106 from $114 at Mizuho

Mizuho lowered the firm’s price target on Ashland to $106 from $114 and keeps a Buy rating on the shares. The analyst reduced estimates ahead of the fiscal Q4 report as de-stocking continues but says Ashland’s pharma growth remains “grossly undervalued.”